CEO
Akeylink Biotechnology
China
Dr. Zhang received his Ph.D. in Biology from the University of Goettingen, Germany, and completed his postdoctoral training at Southwestern Medical Center (UTSW) in Dallas, Texas, and Memorial Sloan-Kettering Cancer Center (MSK) in New York, USA. He is a seasoned pharmaceutical executive with over 25 years of experience leading more than 10 drug discovery and development programs at Wyeth/Pfizer, P&G Pharmaceuticals, and Allergan/AbbVie. Under his leadership, he has taken 8 candidate compounds to clinical development and contributed to 6 NDA submissions and approvals in several countries, including the most recent NDA approval of a novel best-in-class 3CL protease inhibitor for COVID-19 treatment in 2023 in China